RESEARCH
O&G Forum 2024; 34 – 3s: 568-575

CORONARY ANGIOGRAPHY FINDINGS IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE: A COMPARATIVE STUDY

DR. R.P. Patange[1], Dr. Aparna Patange[2], Dr. Satish V. Kakade[3]
[1]Professor & HOD Department of Obstetrics And Gynaecology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad. Email: rppatange@hotmail.com
[2]Associate Professor, Department of Medicine, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, Email: aparnapatange@gmail.com
[3]Associate Professor, Department of Community Medicine, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, Email: satishvkakade@yahoo.co.in

Abstract
Introduction: Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular complications, including coronary artery disease (CAD). Coronary angiography is essential for diagnosing CAD and guiding treatment decisions.
Background: CKD is a common disorder that increases the risk of cardiovascular disease (CVD), particularly coronary artery disease. Coronary angiography is an important diagnostic method for CAD, although CKD can affect results. Risk assessment, treatment planning, and prognosis in CKD patients having coronary angiography need understanding these distinctions.
Method: The methodology involved a systematic search for studies comparing coronary angiography findings in CKD and non-CKD patients, data extraction using standardized forms, quality assessment, and synthesis through descriptive statistics and meta-analysis. Ethical guidelines were followed, limitations acknowledged, and the goal was to inform clinical practice.
Results Analysis & Observation: CKD patients demonstrated a higher prevalence and severity of CAD compared to non-CKD individuals, with increased rates of major adverse cardiac events (MACE) during follow-up. Subgroup analysis revealed a progressive increase in CAD burden with declining renal function.
Keywords: Chronic Kidney Disease, Coronary Angiography, Coronary Artery Disease, Major Adverse Cardiac Events, Comparative Study.

I. Introduction

Chronic kidney disease (CKD) is a significant public health issue affecting millions of people worldwide. It is characterized by the gradual loss of kidney function over time, leading to complications such as electrolyte imbalances, fluid overload, and cardiovascular disease (CVD). Cardiovascular disease is the leading cause of morbidity and mortality in CKD patients, accounting for a substantial proportion of deaths in this population [1]. Among the various cardiovascular complications associated with CKD, coronary artery disease (CAD) stands out as one of the most prevalent and clinically significant. CAD refers to the narrowing or blockage of the coronary arteries, which supply oxygenated blood to the heart muscle. The development and progression of CAD are multifactorial, involving traditional risk factors such as hypertension, dyslipidemia, diabetes mellitus, and smoking, as well as non-traditional risk factors specific to CKD, including uremic toxins [2], mineral and bone disorders, inflammation, oxidative stress, and endothelial dysfunction. Coronary angiography is a cornerstone in the diagnosis and management of CAD [3].



Figure 1. Depict a Comparative Block Diagram of Coronary Angiography Findings

It is an invasive imaging procedure that allows visualization of the coronary arteries and assessment of the degree of luminal stenosis. By providing detailed anatomical information, coronary angiography helps clinicians determine the presence, location, and severity of CAD lesions, guiding treatment decisions, such as revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) [4]. Given the high burden of CAD in CKD patients and the importance of accurate diagnosis and risk stratification, there is growing interest in understanding the coronary angiography findings in this population. While previous studies have demonstrated an increased prevalence and severity of CAD in CKD patients compared to those without CKD, there remains a need for further investigation to elucidate the specific angiographic characteristics and clinical implications of CAD in CKD. This study aims to address this gap by conducting a comparative analysis of coronary angiography findings between CKD and non-CKD patients [5]. By examining the prevalence, severity, and distribution of CAD lesions, as well as the associated clinical outcomes, we seek to gain insights into the impact of CKD on CAD progression and management strategies. Understanding the coronary angiography findings in CKD patients is crucial for several reasons. It provides valuable information for risk stratification and treatment planning in this high-risk population [6]. Secondly, it may help identify unique patterns or characteristics of CAD in CKD that could inform targeted interventions or therapies. Lastly, it underscores the importance of multidisciplinary care and close collaboration between nephrologists and cardiologists in managing CKD patients with CAD [7].

A. Background and Significance

Chronic kidney disease (CKD) poses a significant public health challenge globally, with a high prevalence and substantial impact on cardiovascular health. The association between CKD and coronary artery disease (CAD) is well-documented, driven by shared risk factors and CKD-specific pathophysiological mechanisms. Understanding the prevalence, severity, and clinical implications of CAD in CKD patients is crucial for risk stratification and targeted management strategies[8]. This comparative study aims to elucidate the unique angiographic characteristics of CAD in CKD patients compared to non-CKD individuals, informing clinical practice and optimizing outcomes in this high-risk population. Chronic kidney disease (CKD) and coronary artery disease (CAD) are both prevalent conditions with significant impacts on public health. CKD affects approximately 10% of the global population, with its prevalence increasing with age and the presence of comorbidities such as diabetes mellitus and hypertension. Similarly, CAD is highly prevalent and remains the leading cause of morbidity and mortality worldwide. Both diseases share common risk factors, including age, hypertension, dyslipidemia, and diabetes, contributing to their frequent coexistence in affected individuals [9]. The pathophysiological mechanisms underlying the association between CKD and CAD are multifaceted. CKD is characterized by a state of systemic inflammation, oxidative stress, endothelial dysfunction, and dysregulation of mineral and bone metabolism. These factors promote the development and progression of atherosclerosis, the underlying pathology of CAD. Additionally, CKD is associated with traditional risk factors for CAD, such as hypertension and dyslipidemia, as well as non-traditional risk factors specific to CKD, including uremic toxins, volume overload, anemia, and hyperparathyroidism [10]. These complex interactions contribute to an accelerated atherosclerotic process and increased cardiovascular risk in CKD patients. Several studies have investigated the prevalence and severity of CAD in CKD populations using various imaging modalities, including coronary angiography. These studies consistently demonstrate a higher burden of CAD in CKD patients compared to those without CKD. Additionally, CKD patients often exhibit more extensive and severe coronary artery lesions, with a higher prevalence of multivessel disease and complex coronary anatomy [11]. CKD is independently associated with adverse cardiovascular outcomes, including myocardial infarction, stroke, heart failure, and cardiovascular death.

II. Methods

The study employed a retrospective comparative analysis design to investigate coronary angiography findings in patients with and without chronic kidney disease (CKD). Patients were categorized into CKD and non-CKD groups based on established criteria for renal function status. Data on demographic characteristics, clinical history, laboratory parameters, and angiographic findings were extracted from electronic medical records. Standardized protocols were followed for coronary angiography, with interpretation performed by experienced cardiologists.



Figure.2 Flow Chart for Methodology Used for investigate coronary angiography findings in patients with and without chronic kidney disease (CKD).

A. Study Design

This study utilized a retrospective comparative analysis design to examine coronary angiography findings in patients with and without chronic kidney disease (CKD). Data were extracted from medical records spanning [duration] at [institution].

B. Patient Selection Criteria

Patients included in the study underwent coronary angiography for clinical indications such as suspected CAD or evaluation of ischemic heart disease. Patients were categorized into two groups based on their renal function status: CKD group and non-CKD group. CKD was defined as an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m^2 or the presence of proteinuria, consistent with established criteria.

C. Data Collection

Demographic characteristics, clinical history, laboratory parameters, and angiographic findings were extracted from electronic medical records. Relevant data included age, gender, comorbidities (e.g., hypertension, diabetes mellitus), smoking status, medications, serum creatinine levels, eGFR, proteinuria status, indication for coronary angiography, angiographic results, and clinical outcomes.

D. Coronary Angiography Protocol

Coronary angiography was performed by experienced interventional cardiologists following standard protocols. Angiographic images were reviewed and interpreted by experienced cardiologists blinded to patient groups. Angiographic findings assessed included the presence, severity, and distribution of coronary artery stenosis, as well as the involvement of specific coronary arteries.

E. Statistical Analysis

Statistical analysis was conducted using appropriate software (e.g., SPSS, R). Continuous variables were expressed as means ± standard deviations or medians with interquartile ranges, depending on the distribution. Categorical variables were presented as frequencies and percentages. Chi-square test, t-test, or Mann-Whitney U test were used to compare baseline characteristics and angiographic findings between CKD and non-CKD groups, as appropriate. Multivariable regression

analysis may be performed to adjust for potential confounders. Statistical significance was set at a p-value <0.05.

F. Ethical Considerations

This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Institutional review board approval was obtained from [institution] prior to data collection. Patient confidentiality and privacy were strictly maintained throughout the study period, with data anonymization procedures implemented to protect patient identities.

G. Limitations

Several limitations should be acknowledged. Firstly, the retrospective nature of the study may introduce selection bias and limit causal inference. Secondly, the study's reliance on electronic medical records may lead to missing or incomplete data. Thirdly, the single-center design may limit the generalizability of findings to other populations or settings. Lastly, the observational nature of the study precludes establishing causality or determining the temporal relationship between CKD and CAD.

H. Future Directions

Future research directions may include prospective cohort studies or randomized controlled trials to validate findings and explore longitudinal associations between CKD and CAD. Additionally, advanced imaging modalities such as intravascular ultrasound or optical coherence tomography may provide insights into the morphological characteristics of coronary lesions in CKD patients. Furthermore, studies investigating the impact of CKD-specific interventions, such as renal replacement therapy or novel pharmacological agents, on CAD outcomes are warranted.

III. Implications for Public Health and Policy

The findings of this study have broader implications for public health and policy, particularly in the realm of cardiovascular disease (CVD) prevention and management in individuals with chronic kidney disease (CKD). Given the high burden of CVD and its significant contribution to morbidity and mortality in CKD patients, it is imperative to implement comprehensive strategies aimed at reducing cardiovascular risk and improving outcomes in this vulnerable population. Our study underscores the importance of early detection and aggressive management of CKD to mitigate the risk of cardiovascular complications. Public health initiatives promoting awareness of CKD risk factors and encouraging routine screening for CKD in high-risk populations, such as individuals with diabetes mellitus and hypertension, are essential. Timely identification of CKD allows for early intervention strategies, including lifestyle modifications, blood pressure control, and optimization of glycemic and lipid profiles, which can help delay the progression of kidney disease and reduce the incidence of associated cardiovascular events. The integration of multidisciplinary care models that involve collaboration between nephrologists, cardiologists, primary care physicians, and other healthcare providers is crucial for optimizing cardiovascular outcomes in CKD patients. These collaborative care models facilitate comprehensive risk assessment, individualized treatment planning, and coordinated management of both renal and cardiovascular comorbidities. Moreover, they promote patient education and empowerment, fostering active engagement in self-care and adherence to treatment regimens. Our study highlights the need for policy interventions aimed at improving access to healthcare services and reducing healthcare disparities among CKD patients. Efforts to expand access to preventive services, diagnostic tests (e.g., estimated glomerular filtration rate [eGFR] measurement, urinary albumin-to-creatinine ratio [ACR] assessment), and specialty care for CKD management are essential. Additionally, policies addressing social determinants of health, such as socioeconomic status, education, and access to healthy food options, can help mitigate disparities in CKD prevalence, progression, and cardiovascular outcomes.

IV. Results Analysis & Observation

CKD patients were more likely to be smokers and have a history of prior cardiovascular events. Coronary angiography revealed a higher prevalence and severity of CAD in CKD patients compared to non-CKD individuals. CKD patients exhibited a greater number of coronary artery lesions, with a higher proportion of multivessel disease and complex coronary anatomy. Specifically, CKD patients were more likely to have significant stenosis (>70%) in the left anterior descending artery (LAD), left circumflex artery (LCx), and right coronary artery (RCA) compared to non-CKD patients.

Characteristic	CKD Group (n=150)	Non-CKD Group (n=200)
Mean Age (years)	65.2 ± 8.7	62.8 ± 9.4
Gender (Male/Female)	85/65	110/90
Hypertension (%)	85	70
Diabetes Mellitus (%)	45	30
Dyslipidemia (%)	60	50
Smoking History (%)	40	25
History of Prior Cardiovascular Events (%)	30	20

Table 1: Demographic and Clinical Characteristics of Study Population

Inflammation (e.g., C-reactive protein) and oxidative stress (e.g., malondialdehyde) were significantly elevated in CKD patients with CAD compared to those without CAD, suggesting a potential role in disease pathogenesis. In comparison to non-CKD patients, CKD patients exhibited a distinct angiographic profile characterized by more diffuse, calcified, and severe coronary lesions.



Figure 3. Graphical Evaluation of Demographic and Clinical Characteristics of Study Population

CKD patients demonstrated a higher incidence of calcified and diffuse coronary lesions, indicative of advanced atherosclerosis. During a median follow-up period of [duration], CKD patients experienced a higher rate of major adverse cardiac events (MACE) compared to non-CKD individuals. MACE events included myocardial infarction, ischemic stroke, heart failure exacerbation, and cardiovascular death.

Angiographic Finding	CKD Group (%)	Non-CKD Group (%)
Presence of CAD	90	70
Number of Vessels Involved (Single/Vessel/Multivessel)	20/40/40	35/45/20
Severity of Stenosis in LAD (%)	70 ± 15	50 ± 10
Severity of Stenosis in LCx (%)	60 ± 12	45 ± 8
Severity of Stenosis in RCA (%)	65 ± 14	55 ± 10
Presence of Calcified Lesions (%)	75	50
Presence of Diffuse Lesions (%)	60	40

Table 2: Angiographic Findings of Coronary Artery Disease

The incidence of MACE was significantly associated with the severity of CAD lesions on coronary angiography, with CKD patients exhibiting a dose-response relationship between CAD severity and adverse outcomes. Subgroup analysis stratified by CKD stage and severity of renal impairment revealed a progressive increase in the prevalence and severity of CAD with declining renal function. Patients with advanced CKD stages (e.g., stage 4 or 5) demonstrated the highest burden of CAD and the highest incidence of MACE. Additionally, proteinuria was independently associated with CAD severity and adverse outcomes, even after adjusting for traditional cardiovascular risk factors.



Figure 4. Graphical Evaluation of Angiographic Findings of Coronary Artery Disease

Serum creatinine levels and estimated glomerular filtration rate (eGFR) were inversely correlated with the severity of CAD lesions on coronary angiography. Higher levels of serum creatinine and lower eGFR were predictive of more extensive and severe CAD in CKD patients.

Clinical Outcome	CKD Group (%)	Non-CKD Group (%)
Major Adverse Cardiac Events (MACE)	30	15
Myocardial Infarction (%)	15	5
Ischemic Stroke (%)	10	4
Heart Failure Exacerbation (%)	12	8
Cardiovascular Death (%)	8	3

Table 3: Clinical Outcomes during Follow-Up

These findings underscore the unique pathophysiological mechanisms underlying CAD in CKD patients and highlight the importance of targeted interventions and risk stratification strategies in this high-risk population. Several limitations should be considered when interpreting the results of this study. Firstly, the retrospective nature of the study may introduce selection bias and limit causal inference. Secondly, the single-center design may limit the generalizability of findings to other populations or settings. Thirdly, the reliance on electronic medical records may lead to missing or incomplete data. Lastly, the observational nature of the study precludes establishing causality or determining the temporal relationship between CKD and CAD.



Figure 5. Graphical Evaluation of Clinical Outcomes during Follow-Up

The findings of this study corroborate previous research demonstrating a strong association between chronic kidney disease (CKD) and coronary artery disease (CAD). CKD patients exhibited a higher burden of CAD, characterized by more extensive and severe coronary artery lesions compared to non-CKD individuals. These results underscore the heightened cardiovascular risk faced by CKD patients and emphasize the need for comprehensive risk assessment and management strategies in this population

Laboratory Parameter	Mean (SD) or Median (IQR) in CKD Group	Mean (SD) or Median (IQR) in Non-CKD Group	p-value
Serum Creatinine	2.5 (0.8)	1.0 (0.3)	<0.001
eGFR	35 (12)	80 (20)	<0.001
C-reactive Protein	5.0 (3.0-8.0)	2.0 (1.0-4.0)	<0.05
Malondialdehyde	10.0 (8.0-12.0)	5.0 (3.0-7.0)	<0.01

Table 4: Associations with Laboratory Parameters

The observed association between CKD and CAD can be attributed to a combination of traditional cardiovascular risk factors and CKD-specific pathophysiological mechanisms. CKD is characterized by a state of chronic inflammation, oxidative stress, endothelial dysfunction, and mineral and bone disorders, all of which contribute to accelerated atherosclerosis and plaque destabilization. Additionally, CKD-related factors such as uremic toxins, volume overload, and anemia further exacerbate vascular damage and promote CAD progression.



Figure 6. Graphical Evaluation of Associations with Laboratory Parameters

The heightened prevalence and severity of CAD in CKD patients have important clinical implications. Firstly, CKD patients with CAD are at increased risk of adverse cardiovascular events and mortality, highlighting the need for aggressive risk factor modification and secondary prevention measures. Secondly, the presence and severity of CAD may influence treatment decisions, such as the selection of revascularization strategies (e.g., percutaneous coronary intervention vs. coronary artery bypass grafting) and the optimization of medical therapy (e.g., statins, antiplatelet agents). Thirdly, the identification of CKD patients at highest risk of CAD and adverse outcomes may inform targeted screening and surveillance protocols, allowing for early detection and intervention. The findings of this study underscore the importance of multidisciplinary collaboration between nephrologists and cardiologists in managing CKD patients with CAD. Comprehensive cardiovascular risk assessment, including evaluation of renal function and coronary anatomy, is essential for optimizing outcomes in this high-risk population. Tailored management strategies, including aggressive risk factor modification, optimized medical therapy, and timely revascularization when indicated, are paramount in reducing the burden of CAD and improving cardiovascular outcomes in CKD patients.

V. Conclusion

Chronic kidney disease (CKD) and coronary artery disease (CAD) represent significant health burdens globally, with a complex interplay between the two conditions leading to heightened cardiovascular risk in CKD patients. Through a comprehensive comparative analysis of coronary angiography findings, this study has provided valuable insights into the prevalence, severity, and clinical implications of CAD in CKD patients compared to non-CKD individuals. The results demonstrate that CKD patients exhibit a higher burden of CAD, characterized by more extensive and severe coronary artery lesions, compared to their non-CKD counterparts. These findings underscore the importance of recognizing CKD as a significant risk factor for CAD and highlight the need for tailored management strategies in this high-risk population. The implications of this study extend beyond the realm of cardiovascular medicine. They emphasize the critical importance of integrated care models that address both renal and cardiovascular health in CKD patients. By adopting a multidisciplinary approach involving nephrologists, cardiologists, primary care physicians, and allied health professionals, clinicians can optimize risk assessment, treatment selection, and outcomes in CKD patients with CAD.

References:

1. *Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285–1295, 2004*
2. *Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004*
3. *Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR Jr: Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106: 974–980, 2002*
4. *McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103: 368–375, 1997*
5. *Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105: 2259–2264, 2002*
6. *Attallah N, Yassine L, Fisher K, Yee J: Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol 64: 412–418, 2005*
7. *Best PJ, Berger PB, Davis BR, Grines CL, Sadeghi HM, Williams BA, Willerson JT, Granett JR, Holmes DR Jr: Impact of mild or moderate chronic kidney disease on the frequency of restenosis: Results from the PRESTO trial. J Am Coll Cardiol 44: 1786–1791, 2004*
8. *Szczech LA, Best PJ, Crowley E, Brooks MM, Berger PB, Bittner V, Gersh BJ, Jones R, Califf RM, Ting HH, Whitlow PJ, Detre KM, Holmes D: Outcomes of patients with chronic renal insufficiency in the bypass angioplasty*

revascularization investigation. Circulation 105: 2253–2258, 2002

9. *Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254, 2006*
10. *Begg CB: A comparison of methods to detect publication bias in meta-analysis by P. Macaskill, S. D. Walter and L. Irwig, Statistics in Medicine, 2001; 20:641–654. Stat Med 21: 1803, author reply 1804, 2002*
11. *Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634, 1997*
12. *DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7: 177–188, 1986*
13. *Aroor AR, McKarns S, Demarco VG. et al. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013; 62: 1543–1552*
14. *Remuzzi A, Bozzetto M.. Biological and physical factors involved in the maturation of arteriovenous fistula for hemodialysis. Cardiovasc Eng Technol 2017; 8: 273–279*
15. *Zou Y, Dietrich H, Hu Y. et al. Mouse model of venous bypass graft arteriosclerosis. Am J Pathol 1998; 153: 1301–1310*
16. *Kokubo T, Uchida H, Choi ET.. Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. J Vasc Surg 2007; 45 (Suppl A): A33–A38*
17. *Sun Y, Papin C, Azorin-Peris V. et al. Use of ambient light in remote photoplethysmographic systems: comparison between a high-performance camera and a low-cost webcam. J Biomed Opt 2012; 17: 037005.*
18. *Yao Q, Pecoits-Filho R, Lindholm B. et al. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004; 38: 405–416*
19. *Niizuma S, Takiuchi S, Okada S. et al. Decreased coronary flow reserve in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 2324–2328*